Recombinant human endostatin adenovirus (Guangzhou dabo biological products)

重组人内皮抑素腺病毒（广州达博生物制品）

Report date: 2025/01/02 16:12:29

Base Information

Drug NameRecombinant human endostatin adenovirus (Guangzhou dabo biological products)
Drug Alias NameRECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS(EA10) INJECTION重组人内皮抑素腺病毒（E10A）注射液E-10AE10-AE-10-A +[8] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionAngiogenesis inhibitorsEndostatin replacements
TargetsEndostatin
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsNasopharyngeal Carcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSun Yat-Sen University
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Dabo Biological Products Co Ltd
Inactive CompaniesGuangzhou Double Bioproducts Co LtdSun Yat-Sen University
Active IndicationsSolid tumours
Inactive IndicationsHead and Neck NeoplasmsNasopharyngeal CarcinomaSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A
Related LinksN/A